Mismatch repair (MMR) corrects replication errors during DNA synthesis. The mammalian MMR proteins also activate cell cycle checkpoints and apoptosis in response to persistent DNA damage. MMR-deficient cells are resistant to cisplatin, a DNA cross-linking agent used in chemotherapy, because of impaired activation of apoptotic pathways. It is shown that postmeiotic segregation 2 (PMS2), an MMR protein, is required for cisplatin-induced activation of p73, a member of the p53 family of transcription factors with proapoptotic activity. The human PMS2 is highly polymorphic, with at least 12 known nonsynonymous codon changes identified. We show here that the PMS2(R20Q) variant is defective in activating p73-dependent apoptotic response to cisplatin. When expressed in Pms2-deficient mouse fibroblasts, human PMS2(R20Q) but not PMS2 interfered with the apoptotic response to cisplatin. Correspondingly, PMS2 but not PMS2(R20Q) enhanced the cytotoxic effect of cisplatin measured by clonogenic survival. Because PMS2(R20Q) lacks proapoptotic activity, this polymorphic allele may modulate tumor responses to cisplatin among cancer patients.
D
NA repair is essential to the maintenance of genome integrity. Defects in DNA repair mechanisms cause developmental abnormalities, premature aging, and cancer (1) . Besides their roles in the repair of DNA damage, eukaryotic DNA repair proteins also participate in the transduction of damage signals to regulate cell cycle checkpoints and programmed cell death (2, 3) . By virtue of their ability to bind damaged DNA, proteins such as the MRE11-RAD50-NBS1 (MRN) complex and the MSH2-MSH6 (MutS␣) complex function as sensors of double-stranded breaks or mismatched base pairs, respectively, to activate repair and checkpoint pathways (4, 5) . The dual role of MutS␣ in repairing mispairs and in activating apoptosis is well established (5) . Defect in mismatch repair (MMR) is associated with increased cancer risk, best illustrated with the human cancer syndrome hereditary nonpolyposis colorectal cancer (HNPCC) (6) . Among 11 MMR proteins identified to date, defects in MLH1, MSH2, and MSH6 account for 95% of the mutations identified in HNPCC patients (7) . Mutations in postmeiotic segregation 2 (PMS2), another MMR gene, have also been linked to increased cancer susceptibility (8) .
The core MMR proteins are functionally divided into two groups: the MutS homology (MSH) and the MutL homology (MLH) proteins, named after prokaryotic proteins with similar functions (9) . The MutS heterodimers, MutS␣ and MutS␤, consisting of MSH2-MSH6 and MSH2-MSH3, recognize mismatched bases and small insertion/deletion mispairs in DNA (5) . The MutS heterodimers initiate DNA repair by recruitment of the MutL␣ complex, consisting of MLH1 and PMS2, although a second MutL-related complex, MLH1-MLH3, also plays a role in MMR (5) . Interaction between MutS and MutL complexes leads to the recruitment of yet other proteins that participate in MMR (5) . Although the biochemistry of prokaryotic MMR is well understood (10) , the eukaryotic MMR mechanism is yet to be fully elucidated.
Oxidation, alkylation, or cross-link damage to DNA can activate MMR protein-dependent cell cycle arrest and apoptosis (11) (12) (13) . The activation of checkpoint and apoptosis by MMR may be the result of either futile repair that generates doublestranded breaks or direct signaling involving interactions between the MMR and other DNA damage response proteins (14) . Supporting the direct signaling model are mouse genetic studies showing that the DNA repair and the proapoptotic functions of Msh2 and Msh6 can be separated by specific substitution mutations in each of the two proteins (15, 16) . It has also been shown that the checkpoint kinase ATR is recruited to and activated by alkylated DNA through the combined action of MutS␣ and MutL␣, further suggesting a direct role of MMR proteins in DNA damage signal transduction (17) .
In a previous report, we showed that the PMS2 subunit of the MutL␣ complex is required for cisplatin to activate the proapoptotic function of p73 (18) . The p73 protein is a transcription factor related to the tumor suppressor p53 and shares the proapoptotic function of p53 (19) . Like p53, p73 is activated by DNA damage and can stimulate p53-independent apoptosis (20) . The requirement for PMS2 in damage-induced activation of p73 provides yet another piece of evidence for the direct signaling function of MMR proteins. The human PMS2 is particularly polymorphic. A number of single-nucleotide polymorphisms (SNPs) have been reported for the human PMS2, with 19 occurring in the coding sequence, of which 12 SNPs result in nonsynonymous codon changes. We have examined several polymorphic PMS2 variants for their interactions with MLH1 and p73. Here, we show that PMS2(R20Q), a variant encoded by one of the PMS2 polymorphic alleles, is defective in activating p73-dependent apoptosis in response to cisplatin.
Results
Interactions of PMS2 Variants with MLH1 and p73. We examined several PMS2 variants for their interactions with MLH1 and p73 ( Fig. 1) . Previous studies have established that formation of the PMS2-MLH1 heterodimer (MutL␣) promotes PMS2 stability (21) . Each of the PMS2 variants examined showed increased levels when coexpressed with MLH1 [supporting information (SI) Fig. S1 ]. PMS2 also interacts with and stabilizes the p73 protein (18) . When coexpressed with human TA-p73␣ (transactivating ␣ isoform of p73) (p73), we observed increased levels of p73 with six of the seven variants tested (Fig. 2 A and B) . However, coexpression of PMS2(R20Q) did not lead to an increase in the p73 protein (Fig. 2 A, fourth and fifth lanes, and B, third and fourth bars). These results suggest that PMS2(R20Q) can be stabilized by MLH1, but it does not stabilize p73.
Previous studies have shown that MLH1 and p73 can each stimulate the nuclear accumulation of PMS2 (18, 22) . (Fig. 2C Left) . In cells expressing PMS2-YFP or PMS2(R20Q)-YFP alone, none of them showed an exclusively nuclear YFP signal. Coexpression with p73 resulted in nuclear accumulation of PMS2-YFP in Ϸ30% of transfected cells (Fig. 2C Right) . Coexpression with p73 also induced the nuclear accumulation of PMS2(R20Q)-YFP in Ϸ20% of transfected cells. These results suggest that the R20Q substitution does not affect the interaction between PMS2 and MLH1 but reduces the interaction with p73.
Cisplatin Does Not Enhance the Interaction of PMS2(R20Q) and p73.
The interaction between PMS2 and p73 is stimulated in cisplatintreated cells (18) . In cells coexpressing HA-p73 with myc-PMS2 or myc-PMS2(R20Q), we detected a low level of HA-p73 in anti-myc immunoprecipitation (IP) before cisplatin treatment (Fig. 3A) . In reciprocal co-IPs, a low level of myc-PMS2 or myc-PMS2(R20Q) was detected in the anti-HA immune complexes (Fig. 3A) . These low levels of co-IPs were dependent on the expression of the appropriately tagged proteins, ruling out nonspecific trapping by the anti-myc or the anti-HA antibodies ( Fig. 3A, lanes 2, 11, and 12) . Thus, PMS2(R20Q) appears to retain the ability to form a complex with p73 at basal state. We then tested whether this interaction can be stimulated by cisplatin ( Fig. 3 B and C) . Transfected cells were incubated for 24 h with different concentrations of cisplatin before the preparation of lysates and IP. The levels of total HA-p73 increased with increasing cisplatin concentrations (Fig. 3B , lanes [5] [6] [7] [8] , and the amount of HA-p73 in the anti-myc IP also increased after cisplatin treatment (Fig. 3B, lanes 1-4) . We have shown that the increased co-IP is not simply the result of higher p73 levels but reflects an enhanced association between PMS2 and p73 in cisplatin-treated cells (18) . With the PMS2(R20Q) variant, however, the enhanced association with p73 was not observed at the cisplatin concentrations examined (Fig. 3C, lanes 1-4) . Correspondingly, the steady-state levels of p73 were not altered by cisplatin treatment (Fig. 3C, lanes 5-8) . Thus, the dosedependent stimulatory effect of cisplatin on the PMS2-p73 complex is not observed with the PMS2(R20Q) variant.
We then examined the association of PMS2 with MLH1 in response to cisplatin. Cells were cotransfected with MLH1, HA-p73, and myc-PMS2 or myc-PMS2(R20Q), treated with cisplatin for 24 h, and then subjected to IP with anti-myc (Fig.  3D) . The immune complexes were solubilized and blotted with anti-myc, anti-HA, and anti-MLH1 antibodies (Fig. 3D ). Similar levels of MLH1 protein were found in the anti-myc IP from cells expressing myc-PMS2 or myc-PMS2(R20Q), and the co-IP MLH1 levels were not altered by cisplatin (lanes 1-6, Center). Again, the co-IP HA-p73 levels increased with increasing concentrations of cisplatin in cells expressing myc-PMS2 but not myc-PMS2(R20Q) (lanes 1-6, Bottom). In other experiments, we found that cisplatin did not alter the half-life of PMS2 (data not shown). Consistent with previous reports (18, 21) , neither PMS2 nor PMS2(R20Q) could be stably expressed in MLH1-deficient cells, and treatment with cisplatin did not lead to an accumulation of PMS2 or PMS2(R20Q) proteins in the absence of MLH1. We tested for the formation of MLH1-PMS2-p73 ternary complex by IP with anti-MLH1. Although we consistently observed co-IP of PMS2 with anti-MLH1, the detection of p73 in anti-MLH1 immune complexes was sporadic, suggesting that the ternary complex of MLH1-PMS2-p73, if formed, was unstable. Furthermore, we were unable to detect MLH1 in anti-HA IPs. These results suggest that formation of the MLH1-PMS2 complex is not regulated by cisplatin, whereas the PMS2-p73 complex is stimulated by cisplatin. Interestingly, the R20Q substitution affected the cisplatin responsiveness of the PMS2-p73 complex.
Cell Death Activation Defect of PMS2(R20Q) After Cisplatin DNA Damage. After finding that cisplatin did not enhance the interaction of PMS2(R20Q) and p73, and knowing that PMS2 was required for the activation of p73 apoptotic function after cisplatin damage (18), we compared the effect of PMS2 and PMS2(R20Q) on the apoptotic response to cisplatin. We stably expressed human PMS2 and PMS2(R20Q) in mouse fibroblasts derived from Pms2-deficient embryos via retroviral-mediated gene transfer (Fig. 4A ). Cells were then treated with cisplatin, and the extent of cell death was assessed by two methods: trypan blue exclusion (Fig. 4B ) and sub-G 1 DNA content (Fig. 4C) . Cisplatin-induced cell death was observed in Pms2-deficient mouse embryo fibroblasts (MEFs) after prolonged incubation (Ͼ36 h), showing that these MEFs can die by PMS2-independent mechanism. Expression of PMS2 did not significantly affect the cell death response to cisplatin (Fig. 4 B and C) . However, expression of PMS2(R20Q) reduced the death response (Fig. 4  B and C) . Cisplatin activates the intrinsic apoptotic pathway leading to cleavage and activation of the initiator caspase-9 and the effector caspase-3 (23) . To examine caspase cleavage, we treated cells with cisplatin for 24 h, transferred them into fresh medium, and examined caspase-9 and caspase-3 at 3 to 16 h after adding fresh medium (Fig. 4D) . The cleavage of caspase-9 and caspase-3 occurred between 3 and 6 h after medium change in Pms2-deficient MEFs and those expressing human PMS2 but not those expressing PMS2(R20Q) (Fig. 4D, lanes 7-9) . At each of the time points between 6 and 16 h after medium change, cells expressing PMS2(R20Q) show lower levels of cleaved caspases compared with vector-or PMS2-expressing cells (Fig. 4D, lanes  7-15) . These results show that PMS2(R20Q) exerts a negative effect on cisplatin-induced cleavage of caspase-9 and caspase-3 in the Pms2-deficient MEFs.
We also performed clonogenic survival assays to compare the long-term effect of PMS2 and PMS2(R20Q) on cisplatininduced cytotoxicity (Fig. 5A ). Cells were treated with cisplatin (8 M) or vehicle control for 1 h, washed free of the drug, and then cultured for 10 days. After fixation and staining with crystal violet, we counted the visible colonies and determined the percentage of colony survival as the ratio of colony numbers in cisplatin-treated dishes to those in the control dishes (Fig. 5A) . The plating efficiency of Pms2-deficient MEFs was between 30 and 35%. After treatment with 8 M cisplatin, between 12 and 15% of the Pms2-deficient MEFs survived to form colonies. Expression of PMS2 decreased the clonogenic survival rate to Ͻ10% (P Յ 0.005), whereas expression of PMS2(R20Q) did not affect the clonogenic survival of MEFs. This result shows that PMS2, but not PMS2(R20Q), sensitizes cells to cisplatin.
PMS2(R20Q)-Defective Response Is Maintained After p73 Overexpres-
sion. The Pms2-deficient MEFs contain 5-15 copies of p73 mRNA per cell, as determined by quantitative real-time RT-PCR experiments (data not shown). However, we were unable to detect the mouse p73 protein in these MEFs; as a result, we could not examine the effect of PMS2 or PMS2(R20Q) on the endogenous p73. We therefore tested whether the ectopic expression of p73 could influence the death response to cisplatin in these cells. Pms2-deficient MEFs stably expressing vector, human PMS2 or PMS2(R20Q) were transfected with plasmids expressing YFP-p73 or YFP, treated with or without 25 M cisdiamminedichloroplatinum (CDDP) for 24 h, and the uptake of propidium iodide (PI) was measured in the YFP-positive cells by FACS analyses (Fig. 5B) . Consistent with previous reports (18, 24) , ectopic expression of YFP-p73 increased the levels of PI uptake even without cisplatin treatment (Fig. 5B, compare   CDDP, bars 2, 4, and 6 with 8, 10, and 12) . Expression of YFP-p73 also accelerated the death response to cisplatin, such that significant levels of PI-positive cells were detected at 24 h after drug addition (Fig. 5B, compare ϩCDDP bars 1, 3 , and 5 with 7, 9, and 11). In cells expressing PMS2, cisplatin-induced death was significantly higher in the YFP-p73-transfected population (Fig. 5B, compare bars 3 and 9) , consistent with previous results (18) . By contrast, this cisplatin-induced and YFP-p73-dependent increase in death was not observed with cells expressing PMS2(R20Q) (Fig. 5B, compare bars 1 and 5) . These results support the conclusion that PMS2(R20Q) is defective in transducing cisplatin damage signal to p73.
Human PMS2 and PMS2(R20Q) Did Not Correct the MMR Defect of
Mouse Pms2-Knockout Cells. It has been reported that the human PMS2 protein cannot correct MMR defects in Pms2-knockout mouse cells (25) . We have independently verified that conclusion with the Pms2-knockout cells reconstituted with retroviral vector, human PMS2, or PMS2(R20Q) (Fig. S2) . We performed single-cell cloning from the stably infected cell populations and then analyzed two microsatellite markers by using diluted genomic DNA samples. The results showed that cells expressing PMS2 or PMS2(R20Q) displayed microsatellite instability that was comparable with those expressing vector alone (Fig. S2) . Thus, the differential apoptotic and clonogenic survival responses to cisplatin occurred in cells that remained defective for MMR.
Discussion
Genetic polymorphism is a contributing factor to the phenotypic diversity of the human population. In the clinical arena, knowing the effects of polymorphic alleles on the cause or the treatment of diseases is of importance, and such knowledge is essential to the development of personalized medicine. The degree of polymorphism among human genes is highly variable and probably related to the gene function and the selective pressures on that function. In this work, we examined several variants of the human PMS2, which is highly polymorphic, and we found one of the variants to exhibit a defect in promoting the cellular apoptotic response to cisplatin. It will be of interest as future work to determine whether the PMS2(R20Q) allele is associated with increased resistance to cisplatin among cancer patients treated with this chemotherapeutic agent.
The PMS2 gene encodes a MutL-homologous protein that forms a heterodimer with MLH1; and the resulting complex, MutL␣, interacts with MutS␣/␤ to activate MMR (26, 27) . MLH1 deficiency is associated with the development of many cancer types (28, 29) , and PMS2 deficiency is associated with HNPCC and Turcot's syndrome (30) (31) (32) . The tumor suppression function of MutL␣ is attributed to its essential role in MMR (10). However, MutL␣-dependent activation of checkpoint pathways may also contribute to tumor suppression (14) . The genetic evidence that DNA repair and proapoptotic functions of MSH2 or MSH6 can be separated by specific substitution mutations have suggested that these two biological functions may involve different conformations of the MutS␣ complex (15, 16) . Our finding that PMS2(R20Q) is proficient in binding MLH1 but deficient in activating p73 is consistent with that idea, i.e., the repair and proapoptotic functions of MutL␣ may also involve different conformations.
The codon-20 of PMS2 is not conserved among human, mouse, or yeast, in keeping with its being a polymorphic codon in the human PMS2. It is therefore not surprising to find that the R20Q substitution does not affect the PMS2-MLH1 interaction, nor does it affect the basal interaction between PMS2 and p73. Interestingly, however, R20Q disrupts cisplatin-induced PMS2-p73 interaction. According to the crystal structure of the Nterminal 40-kDa fragment of the human PMS2 protein (33) , R20 is in the disordered L1 loop that is N-terminal to the highly conserved ATPase domain found in MutL homologs. By comparison with the crystal structure of the bacterial MutL homodimer (34), the disordered L1 loop is likely to be involved in the PMS2-MLH1 interaction. We propose two possibilities for how this L1 loop may play a role in the cisplatin-enhanced interaction between PMS2 ad p73. In the first scenario, the L1 loop may dissociate from MLH1 after recruitment of the MutL␣ complex to platinum-damaged DNA and thus promotes PMS2 binding to p73. If so, R20Q may hinder this dissociation of PMS2 from MLH1 and thus interfere with the cisplatin-induced interaction between PMS2 and p73. In the second scenario, the L1 loop may contact p73 directly, and R20Q may prevent this contact site from being created in response to cisplatin. Unlike the bacterial MutL protein, the N-terminal PMS2 fragment exhibits ATPase activity as a monomer (33) , suggesting that PMS2 may undergo ATP/ADP conformational transitions without MLH1. It is conceivable that the activation of p73 may involve monomeric PMS2 that is dissociated from MLH1 in response to cisplatin. Because monomeric PMS2 is highly unstable (21, 35) , formation of the PMS2-p73 complex may require additional factors that remain to be identified.
Materials and Methods
Cell Lines. HEK 293T, Phoenix eco packaging cells (Orbigen), 3T3 derived from Pms2 Ϫ/Ϫ MEF (c18.2 line) (36) , and COS-1 cells were grown in DMEM supplemented with 10% FBS and penicillin/streptomycin (50 units/ml, each) (Cellgro).
Quantitation of Protein Levels in Transient
Cotransfections. 293T cells were cotransfected with the indicated combination of plasmids: one of tested pCMV-myc-PMS2 variants, pCMV-MLH1, pcDNA3-HA-p73, or empty pcDNA3(ϩ) vector (Invitrogen) by using FuGENE 6 (Roche Molecular Biochemicals). Cells were lysed in RIPA buffer, sonicated, and briefly centrifuged at 10,000 ϫ g. To normalize for transfection efficiency, ␤-galactosidase expression plasmid (pCMV-␤-gal) was added to the transfection mixture, and loading of lysates was determined by the level of enzymatic activity in each lysate, to assure loading of equal number of transfected cells. At 48 h after transfection, whole-cell lysates were analyzed by immunoblotting with standard protocol. The relative expression level of proteins was determined by densitometry. Levels of protein expression in vector-cotransfected cells were set as 1.
Nuclear Accumulation Assay. pEYFP-C1 (Clontech) was used for the production of YFP-PMS2 or YFP-PMS2 R20Q fusion proteins. COS-1 cells seeded onto sterile coverslips were transfected with YFP-PMS2 or YFP-PMS2(R20Q) and in the same time cotransfected with MLH1, p73, or empty vector for a control. We introduced 0.5 g of each plasmid to cells by using FuGENE 6. After 48 h, cells where fixed with 3.7% paraformaldehyde and stained with 1 g/ml Hoechst 33258 DNA. Coverslips where washed with PBS and visualized by a DeltaVision deconvolution microscope with Softworks software (Applied Precision). To determine nuclear-only YFP, we used an epifluorescence microscope (Zeiss) at ϫ400 magnitude. Ten randomly chosen fields were counted per experiment.
Cisplatin Treatment of MEFs. c18.2 cells (1 ϫ 10 6 ) were seeded in a 6-cm dish, and the culture was incubated overnight, followed by treatment with 25 M cisplatin for 24 h. MEFs are mostly arrested in late S and G2/M at this time point. To induce apoptosis, the cultures were washed with medium and incubated in fresh medium containing 25 M cisplatin for another 24 h. Cells were collected at the indicated time points during the second 24 h of incubation in triplicate for the analyses of cell death.
Clonogenic Survival Assay. Cells were seeded at a density of 200 cells per each well of a 6-well dish in 2 ml of DMEM ϩ 10% FBS. The next day they were treated with 8 M CDDP for 1 h or vehicle as control. After washing with medium three times, cells were cultured further for 10 days with fresh medium added at day 5. After 10 days, medium was removed, and cells were washed in PBS and stained for 30 min with staining solution (0.25% crystal violet, 3.5% formaldehyde, 80% methanol). The wells were washed with water, and colonies were counted. The percentage of colony survival was calculated as a number of colonies in CDDP-treated wells divided by a number of colonies in untreated, control wells. Clonogenic survival of Pms2-deficient MEFs expressing vector, PMS2, or PMS2(R20Q) was performed in triplicate. Results from four independent experiments are shown. PI Uptake Assay. c18.2 cells (3 ϫ 10 5 ) were seeded in each well of a 6-well dish. Cells were transfected with pYFP-p73 plasmid or empty pYFP plasmid while still in suspension, by using 2 g of each plasmid DNA per well in 6 l of Single-Cell Cloning and Microsatellite Instability. Pms2-knockout MEFs stably infected with retroviral vector, retroviral-PMS2, or retroviral-PMS2R20Q were plated sparsely and cultured for 3 weeks to allow the growth of individual colonies, which were picked and expanded in culture for a period of 6 weeks, and the expression of PMS2 or PMS2(R20Q) was examined by immunoblotting with anti-PMS2 antibodies. Genomic DNA was prepared by two independently derived clones from each of the three populations. Mutations in microsatellite sequences were assayed by PCR of single target molecules, as is described in SI Materials and Methods.
Statistical Analysis. For trypan blue assay and sub-G 1 measurement, statistical significance was determined by repeated-measurement ANOVA and ANOVA for each time point (WinStat). For protein stability assay, a t test for independent sample was used. For clonogenic survival and PI exclusion assay, ANOVA was used to determine statistical significance.
Procedures for immunoblotting, co-IP, PMS2 variant construction, recombinant retroviral infection, trypan blue exclusion assay, and microsatellite instability assay are described in SI Materials and Methods.
